DNA & Genetics Novartis Inks Up-to-$5.7B Second Collaboration with Monte RosaBy adminSeptember 17, 20250 Nearly a year after licensing Monte Rosa Therapeutics’ Phase II-bound autoimmune disease candidate MRT-6160, Novartis has agreed to partner on…
